Cleveland Alzheimer's Disease Research Center

克利夫兰阿尔茨海默病研究中心

• 批准号: 10204392
• 负责人: JAMES Bruce LEVERENZ
• 金额: $ 16.1万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10204392
• 关键词: Adult; Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; COVID-19; COVID-19 pandemic; Clinic; Clinical; Clinical Research; Cognitive; Collection; Communication; Communities; Consent; Contracts; Country; Dementia; Disease; Effectiveness; Elderly; Enrollment; Ethics; Evaluation; Face; Foundations; Funding; Future; Guidelines; Health system; Healthcare; Height; Heterogeneity; Image; Individual; Informed Consent; Infrastructure; International; Interruption; Interview; Legal; Lewy Body Dementia; Measures; Medical; Medical center; Methodology; Minority Enrollment; National Institute on Aging; Nevada; Ohio; Participant; Pathologic; Pathology; Patients; Persons; Physicians; Population; Prion Diseases; Process; Public Health; Qualitative Research; Research; Research Personnel; Risk; Sampling; Science; Speed; Structure; Sustainable Development; Technology; Telephone; United States National Institutes of Health; Universities; University Hospitals; clinical care; experience; improved; innovation; mild cognitive impairment; pandemic disease; patient population; programs; recruit; research to practice; support tools; theories

OVERALL PROJECT SUMMARY The Cleveland Alzheimer’s Disease Research Center (CADRC) is a collaborative effort amongst physicians and investigators from Case Western Reserve University (CWRU), the Cleveland Clinic Foundation (CCF), the Metro Health System (MHS), University Hospitals (UH), and the Louis Stokes Cleveland VA Medical Center (LSVA), to establish a National Institute on Aging (NIA) funded Alzheimer’s disease research center. The CADRC would represent a rich clinical and research community and an estimated 220,000 Ohioans who suffer from Alzheimer’s disease (AD). Currently there is no Alzheimer’s Disease Research Center in Ohio. The CADRC will bring together the considerable expertise from the medical and academic communities in northeast Ohio to focus on one of the largest health care crises facing our country. The CADRC will be focused on the increasingly recognized clinical and pathologic heterogeneity observed in AD and AD-Related Dementias (ADRD). The CADRC will create an infrastructure to help speed up the research efforts of local, national and international investigators. The CADRC will participate in the national Alzheimer’s Centers program and contribute to the “big science” possible when centers from around the country collaborate. We will recruit subject samples that northeast Ohio is well situated to study due to unique regional populations or studies (dementia with Lewy bodies and rapidly progressive AD identified by the National Prion Disease Pathology Surveillance Center,) or relevant to our understanding of AD and related dementias (cognitively normal older individuals, AD and mild cognitive impairment). We will add value to the evaluation of these subject samples by adding biofluid collection and analysis and cutting edge imaging. Special emphasis will also be placed on enrollment of minority populations not often well-studied. We are quite encouraged by the collaborative spirit already demonstrated by those participating in the CADRC planning from CWRU, CCF, MHS, UH, and LSVA and from the support we have received from the northeast Ohio community. We believe this is a great opportunity for Ohio to contribute to the greater efforts of the Alzheimer’s Disease Research Centers program and to improve the treatments for these devastating disorders.

整体

项目成果

Cleveland Clinic Cognitive Battery (C3B): Normative, Reliability, and Validation Studies of a Self-Administered Computerized Tool for Screening Cognitive Dysfunction in Primary Care.

• DOI: 10.3233/jad-220929
• 发表时间: 2023
• 期刊: JOURNAL OF ALZHEIMERS DISEASE
• 影响因子: 4
• 作者: Rao, Stephen M.;Galioto, Rachel;Sokolowski, Megan;Pierce, Madelyn;Penn, Lisa;Sturtevant, Anna;Skugor, Blazenka;Anstead, Brent;Leverenz, James B.;Schindler, David;Blum, David;Alberts, Jay L.;Posk, Lori
• 通讯作者: Posk, Lori

High resolution structural and functional MRI of the hippocampus in young adults with Down syndrome.

• DOI: 10.1093/braincomms/fcab088
• 发表时间: 2021
• 期刊: Brain communications
• 影响因子: 4.8
• 作者: Koenig KA;Oh SH;Stasko MR;Roth EC;Taylor HG;Ruedrich S;Wang ZI;Leverenz JB;Costa ACS
• 通讯作者: Costa ACS

Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group.

• DOI: 10.1002/dad2.12235
• 发表时间: 2021
• 期刊: Alzheimer's & dementia (Amsterdam, Netherlands)
• 作者: D'Antonio F;Kane JPM;Ibañez A;Lewis SJG;Camicioli R;Wang H;Yu Y;Zhang J;Ji Y;Borda MG;Kandadai RM;Babiloni C;Bonanni L;Ikeda M;Boeve BF;Leverenz JB;Aarsland D;ISTAART Lewy body dementias Consortia Working Group
• 通讯作者: ISTAART Lewy body dementias Consortia Working Group

Amyloid Precursor Protein Variant, E665D, Associated With Unique Clinical and Biomarker Phenotype.

淀粉样蛋白前体蛋白变体，E665D，与独特的临床和生物标志物表型相关。

• DOI: 10.1177/1533317520981225
• 发表时间: 2021
• 期刊: American journal of Alzheimer's disease and other dementias
• 作者: Abbatemarco,JustinR;Jones,StephenE;Larvie,Mykol;Bekris,LynnM;Khrestian,MariaE;Krishnan,Kamini;Leverenz,JamesB
• 通讯作者: Leverenz,JamesB

Characterization of Prion Disease Associated with a Two-Octapeptide Repeat Insertion.

• DOI: 10.3390/v13091794
• 发表时间: 2021-09-08
• 期刊: Viruses
• 作者: Brennecke N;Cali I;Mok TH;Speedy H;Genomics England Research Consortium;Hosszu LLP;Stehmann C;Cracco L;Puoti G;Prior TW;Cohen ML;Collins SJ;Mead S;Appleby BS
• 通讯作者: Appleby BS